Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10556550 | 0.92 | MEN1 (0.61) | MEN1KMT2ASLC18A3SIGMAR1DRD2 | |
| SCHEMBL17432875 | 0.92 | MEN1 (0.61) | MEN1KMT2ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL11499589 | 0.87 | MEN1 (0.52) | MEN1KMT2ASLC18A3SIGMAR1DRD2 | |
| SCHEMBL11453030 | 0.84 | POLB (0.67) | MEN1KMT2ASIGMAR1DRD2DRD4 | |
| SCHEMBL7329656 | 0.84 | MEN1 (0.74) | MEN1KMT2ASLC18A3SIGMAR1DRD2 | |
| SCHEMBL24460692 | 0.84 | PDE2A (0.52) | SLC18A3SIGMAR1DRD4 | |
| SCHEMBL5577360 | 0.84 | MCHR1 (0.60) | MEN1KMT2ASIGMAR1MCHR1CHRM4 | |
| Oxalic Acid SCHEMBL7329508 | 0.84 | CHRM4 (0.60) | MEN1KMT2ASLC18A3SIGMAR1CHRM4 | |
| SCHEMBL22361376 | 0.79 | MEN1 (0.61) | MEN1KMT2ADRD2DRD4ALDH1A1 | |
| SCHEMBL82298 | 0.79 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | MEN1 80/4885KMT2A 672/4885SLC18A3 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.